ASCO: New Assays May Detect Early Lung Cancer in Blood

Share this content:
ASCO: New Assays May Detect Early Lung Cancer in Blood
ASCO: New Assays May Detect Early Lung Cancer in Blood

WEDNESDAY, June 6, 2018 (HealthDay News) -- Three assays may detect early lung cancer in blood samples using genome sequencing, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Geoffrey R. Oxnard, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues prospectively collected blood from 749 controls (with no cancer diagnosis) and 878 patients with newly-diagnosed untreated cancer, including 127 patients with lung cancer. Three sequencing assays were performed: paired cell-free DNA (cfDNA) and white blood cell (WBC) targeted sequencing for single nucleotide variants/indels; paired cfDNA and WBC whole genome sequencing (WGS) for copy number variation; and cfDNA and WBC whole genome bisulfite sequencing (WGBS) for methylation.

Overall, 127 patients with lung cancer and 580 controls were evaluated. The researchers found that more than 50 percent of the 3,055 nonsynonymous mutations detected across 122 evaluable patients with lung cancer were detected in WBC consistent with clonal hematopoiesis. At a specificity of 98 percent, the WGBS, WGS, and targeted assays detected 41, 38, and 51 percent of early-stage (I to IIIA) cancers, and 89, 87, and 89 percent of late-stage (IIIB to IV) cancers. Five (<1 percent) of the control samples had a cancer-like signal; two of these were subsequently diagnosed with cancer.

"These are promising early results, and next steps are to further optimize the assays and validate results in a larger group of people," Oxnard said in a statement.

The study was funded by GRAIL, Inc.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

More U.S. Teens Are Vaping, but Use of Opioids, Alcohol Falling

More U.S. Teens Are Vaping, but Use of ...

About 37 percent of 12th graders said they had vaped within the previous 12 months

Type 2 Diabetes Risk Lower in Women With Active Migraine

Type 2 Diabetes Risk Lower in Women With ...

Prevalence of active migraine decreased linearly in the 24 years prior to diabetes diagnosis

Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder

Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder

Treatment costs less than extended-release naltrexone without negative impact on outcomes

is free, fast, and customized just for you!




Already a member?

Sign In Now »